Recent topics on α-fetoprotein

Hepatology Research

Volumn 43, Issue 8, 2013, Pages 820-825

  Nakao, Kazuhiko ^a   Ichikawa, Tatsuki ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

fetoprotein; Chronic hepatitis C; Hepatocellular carcinoma; Highly sensitive Lens culinaris agglutinin reactive fetoprotein; Liver transplantation; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; PEGINTERFERON; RIBAVIRIN; SORAFENIB;

ADULT; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE PROGRESSION; FEMALE; HEPATITIS C; HUMAN; LENTIL; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE RISK; REVIEW; RISK FACTOR;

EID: 84878204649     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12052     Document Type: Review

References (57)

1. Nakata K, Motomura M, Nakabayashi H, Ido A, Tamaoki T. A possible mechanism of inverse developmental regulation of alpha-fetoprotein and albumin genes. Studies with epidermal growth factor and phorbol ester. J Biol Chem 1992; 267: 1331-1334.
2. Tsutsumi T, Ido A, Nakao K etal. Reciprocal regulation of alpha-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Gastroenterology 1994; 107: 499-504.
3. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004; 99: 860-865.
4. Schiødt FV, Ostapowicz G, Murray N etal. Alpha-fetoprotein and prognosis in acute liver failure. Liver Transpl 2006; 12: 1776-1781.
5. Sherman M. The resurrection of alphafetoprotein. J Hepatol 2010; 52: 939-940.
6. Riaz A, Ryu RK, Kulik LM etal. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009; 27: 5734-5742.
7. Li HM, Ikeda H, Nakabayashi H, Nishi S, Sakai M. Identification of CCAAT enhancer binding protein alpha binding sites on the human alpha-fetoprotein gene. Gene 2007; 389: 128-135.
8. Nakabayashi H, Koyama Y, Suzuki H etal. Functional mapping of tissue-specific elements of the human alpha-fetoprotein gene enhancer. Biochem Biophys Res Commun 2004; 318: 773-785.
9. Peterson ML, Ma C, Spear BT. Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer. Semin Cancer Biol 2011; 21: 21-27.
10. Kajiyama Y, Tian J, Locker J. Characterization of distant enhancers and promoters in the albumin-alpha-fetoprotein locus during active and silenced expression. J Biol Chem 2006; 281: 30122-30131.
11. Jin L, Long L, Green MA, Spear BT. The alpha-fetoprotein enhancer region activates the albumin and alpha-fetoprotein promoters during liver development. Dev Biol 2009; 336: 294-300.
12. Perincheri S, Dingle RW, Peterson ML, Spear BT. Hereditary persistence of alpha-fetoprotein and H19 expression in liver of BALB/cJ mice is due to aretrovirus insertion in the Zhx2 gene. Proc Natl Acad Sci U S A 2005; 102: 396-401.
13. Xie Z, Zhang H, Tsai W etal. Zinc finger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver. Proc Natl Acad Sci U S A 2008; 105: 10859-10864.
14. Shen H, Luan F, Liu H etal. ZHX2 is a repressor of alpha-fetoprotein expression in human hepatoma cell lines. J Cell Mol Med 2008; 12: 2772-2780.
15. Lv Z, Zhang M, Bi J, Xu F, Hu S, Wen J. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. Am J Clin Pathol 2006; 125: 740-746.
16. Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology 2007; 46: 1541-1547.
17. Yue X, Zhang Z, Liang X etal. Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinomacell proliferation and represses expression of Cyclins A and E. Gastroenterology 2012; 142: 1559-1570.
18. Kojima K, Takata A, Vadnais C etal. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun 2011; 2: 338.
19. Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol 2012; 10: 428-433.
20. Tateyama M, Yatsuhashi H, Taura N etal. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis Cvirus. J Gastroenterol 2011; 46: 92-100.
21. Abdoul H, Mallet V, Pol S, Fontanet A. Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype. PLoS ONE 2008; 3: e2391.
22. Chen TM, Huang PT, Tsai MH etal. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylatedinterferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol 2007; 22: 669-675.
23. Murashima S, Tanaka M, Haramaki M etal. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 2006; 51: 808-812.
24. Nomura H, Kashiwagi Y, Hirano R etal. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: a pilot study. Hepatol Res 2007; 37: 490-497.
25. Kajiwara E, Ooho A, Yamashita N. Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels. Hepatol Res 2012; 42: 254-263.
26. Tamura Y, Yamagiwa S, Aoki Y etal. Niigata Liver Disease Study Group. Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci 2009; 54: 2530-2537.
27. Osaki Y, Ueda Y, Marusawa H etal. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J Gastroenterol 2012; 47: 444-451.
28. Akuta N, Suzuki F, Kawamura Y etal. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. J Med Virol 2008; 80: 1354-1362.
29. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410.
30. Akuta N, Suzuki F, Kawamura Y etal. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007; 46: 1357-1364.
31. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol 2011; 83: 1016-1022.
32. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplant for hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35: 987-999.
33. Duvoux C, Roudot-Thoraval F, Decaens T etal. Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-994.
34. Muscari F, Guinard JP, Kamar N, Peron JM, Otal P, Suc B. Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. World J Surg 2012; 36: 1824-1831.
35. Xu X, Ke QH, Shao ZX etal. The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci 2009; 54: 385-388.
36. Cescon M, Ravaioli M, Grazi GL etal. Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant 2010; doi: 10.1155/2010/904152.
37. Han K, Tzimas GN, Barkun JS etal. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39-45.
38. Mailey B, Artinyan A, Khalili J etal. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011; 146: 26-33.
39. Todo S, Furukawa H, Tada M, Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007; 13: S48-54.
40. Wang ZX, Song SH, Teng F etal. A single-center retrospective analysis of liver transplantation on 255 patients with hepatocellular carcinoma. Clin Transplant 2010; 24: 752-757.
41. Fujiki M, Takada Y, Ogura Y etal. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009; 9: 2362-2371.
42. Yao FY, Kerlan RK Jr, Hirose R etal. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819-827.
43. Merani S, Majno P, Kneteman NM etal. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-819.
44. Toso C, Dupuis-Lozeron E, Majno P etal. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012; 56: 149-156.
45. Llovet JM, Ricci S, Mazzaferro V etal. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
46. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
47. Personeni N, Bozzarelli S, Pressiani T etal. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012; 57: 101-107.
48. Yau T, Yao TJ, Chan P etal. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011; 16: 1270-1279.
49. Kuzuya T, Asahina Y, Tsuchiya K etal. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 251-258.
50. Kawaoka T, Aikata H, Murakami E etal. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced hepatocellular carcinoma patients treated with Sorafenib. Oncology 2012; 83: 192-200.
51. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996; 111: 996-1001.
52. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 2010; 55: 3576-3583.
53. Hanaoka T, Sato S, Tobita H etal. Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in patients with chronic liver disease. J Gastroenterol Hepatol 2011; 26: 739-744.
54. Toyoda H, Kumada T, Tada T etal. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20ng/mL. Cancer Sci 2011; 102: 1025-1031.
55. Nouso K, Kobayashi Y, Nakamura S etal. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol 2011; 26: 1195-1200.
56. Kobayashi M, Hosaka T, Ikeda K etal. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011; 41: 1036-1045.
57. Toyoda H, Kumada T, Tada T. Highly sensitive Lens culinaris agglutinin-reactive α-fetoprotein: a new tool for the management of hepatocellular carcinoma. Oncology 2011; 81: 61-65.